Genmab A/S announced the appointment of Judith Klimovsky, MD, as Executive Vice President and Chief Development Officer (CDO). Dr. Klimovsky will lead the company’s global product development activities and will join the Executive team of Chief Executive Officer, Dr. Jan van de Winkel and Chief Financial Officer, David Eatwell. Dr. Klimovsky will be responsible for Genmab’s product development strategy in line with the company’s corporate strategy and the 2025 Vision. Dr. Klimovsky has had a distinguished career in drug development, most recently serving as Senior Vice President and Global Head, Oncology Clinical Development, at Novartis. She is a hematologist by training with extensive experience in various roles at BMS, Merck and Novartis, as well as having experience in hematology clinical practice. Dr. Klimovsky will join Genmab on February 13, 2017 and will be based at the company’s Princeton, United States location, whilst travelling regularly to the company’s locations in Copenhagen, Denmark and Utrecht, The Netherlands.